Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
The rate of permanent discontinuation of different ICIs because of treatment-related adverse events
| Indication | Drug | Discontinuation rate, % |
| Metastatic melanoma | Ipilimumab Nivolumab Ipilimumab+nivolumab Pembrolizumab |
14.860, 9.461 7.760 36.460 6.961 (every 3 weeks), 461 (every 2 weeks) |
| Metastatic renal cell cancer | Ipilimumab+nivolumab Nivolumab |
2262 863 |
| NSCLC | Pembrolizumab | 964 |
ICI, immune checkpoint inhibition.
